Local Injection Methylene Blue Combined With Radiation in HNSCC Patients (NCT07435415) (2025)

Government Record · China Medical University Hospital (sponsor) · August 2025

China Medical University Hospital (sponsor), 2025-08: Registered early-phase-1 trial at a Taiwanese centre testing intratumoral methylene blue injections with concurrent radiotherapy in 10 patients with locally recurrent head and neck squamous cell carcinoma resistant to radiation. Status active, not recruiting; no results posted.

Receive weekly injections of Methylene Blue or placebo into the tumor over six weeks.

China Medical University Hospital (sponsor), 2025-08: Registered early-phase-1 trial at a Taiwanese centre testing intratumoral methylene blue injections with concurrent radiotherapy in 10 patients with locally recurrent head and neck squamous cell carcinoma resistant to radiation. Status active, not recruiting; no results posted. Record field quote from the registry brief summary (not prose from a paper), hence MEDIUM. Registry: ClinicalTrials.gov NCT07435415. Sponsor: China Medical University Hospital (Taiwan). Phase: EARLY_PHASE1. Status: ACTIVE_NOT_RECRUITING. Enrollment: 10. Start 2025-08-01; primary completion 2026-12-31. Design: single-centre, intratumoral methylene blue or placebo weekly for six weeks plus six weeks of radiotherapy; primary outcome is any unexpected severe adverse event. REGISTERED, NO RESULTS POSTED – bearing PARTLY SUPPORTS for that reason. This is the only registered placebo-controlled radiosensitiser trial of methylene blue in cancer found in this run. Study type: regulatory record.